A Sensing Platform for Rapid at Home-Test of COVID-19

摘要 自美国(美国)报告首例新冠肺炎病例以来2020年1月21日，它 已被确定影响90万活动性病例和50000例死亡。目前，新冠肺炎 主要通过三种技术进行诊断，即逆转录聚合酶链 反应(RT-PCR)、基因测序和胸部CT。然而，限制 样本收集和运输以及试剂盒性能方面的问题，而不能充分获得 先进的乐器技术，往往不能在新冠肺炎首发时报告领先 将这种传染病传播到更广泛的社区。此外，研究人员发现，至少 在160个不同的完整人类中，通过氨基酸变化区分的三个中心变异 SARS-CoV-2基因组序列。这限制了当前可用的 商业新冠肺炎套件。在这项建议中，我们提出了一种新的筛选活动的方法 新冠肺炎纸基侧向流动分析介导的比色POC生物传感器 将能够使用专门设计的反义来检测SARS-CoV-2基因序列 寡核苷酸(ASO)。这种选择性检测SARS-CoV-2病毒的独特方法消除了 SARS-CoV-2最常见的基因组变异可能导致误解 关于当前新冠肺炎传感试剂盒的局限性。

ABSTRACT Since the first case of COVID-19 was reported in the United States (U.S.) on January 21st, 2020, it has already been ascertained to affect >900K active cases with >50K deaths. Currently, COVID-19 is being diagnosed primarily by three techniques, i.e. reverse-transcription polymerase chain reaction (RT-PCR), gene sequencing and chest computed tomography (CT). However, limitations of sample collection and transportation, as well as kit performance with inadequate access to advanced instrumental techniques, often cannot report COVID-19 at its initial presentation leading to the spread of this infectious disease to a wider community. Moreover, researchers found at least three central variants, distinguishable by amino acid changes, among 160 different complete human SARS-CoV-2 genome sequences. This limits the universal applicability of the currently available commercial COVID-19 kits. In this proposal we present a novel approach for screening of active COVID-19 cases with a paper based lateral flow assay mediated colorimetric POC biosensor that would be able to detect the SARS-CoV-2 gene sequence using specifically designed antisense oligonucleotides (ASO). This unique approach for selective sensing of SARS-CoV-2 eliminates the possibility of misinterpretation arisen due to the genomic variants of SARS-CoV-2 which is the most concerning limitation of the current COVID-19 sensing kits.